SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. vol. VII. Lyon: IARC, 1997.
  • 2
    Henderson BE, Pike M, Bernstein L, Ross LK. Breast cancer. In: SchottenfeldD, FraumeniJF, eds. Cancer epidemiology and prevention. New York: Oxford University Press, 1996. 102239.
  • 3
    Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A, Pouillart P. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic pattern. Cancer 1996; 77: 11320.
  • 4
    World Health Organization. Histological typing of breast tumours. Second edition. Geneva, 1981.
  • 5
    Bouvet M, Ollila DW, Hunt KK, Babiera GV, Spitz FR, Guiliano AE, Strom EA, Ames FC, Ross MI, Singletary SE. Role of conservative therapy for invasive lobular carcinoma of the breast. Ann Surg Oncol 1997; 4: 6504.
  • 6
    Peiro G, Bornstein BA, Conolly JL, Gelman R, Hetelekidis S, Nixon AJ, Recht A, Silver B, Harris JR, Schnitt SJ. The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 2000; 59: 4954.
  • 7
    Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 2000; 88: 25619.
  • 8
    Bouchardy C. Switzerland, Geneva. In: ParkinDM, WhelanSL, FerlayJ, RaymondL, YoungJ, eds. Cancer incidence in five continents. vol. VII. Lyon: IARC, 1997. 6669.
  • 9
    World Health Organisation. ICD-O. International classification of diseases for oncology, 1st ed. Geneva: WHO, 1976.
  • 10
    Shambough EM, Gloecker Ries LA, Young JL, Kruse MA, Platz CE, Ryan RF. SEER extent of disease—1988. Codes and coding instructions, 2nd ed. Washington DC: National Institutes of Health, 1992.
  • 11
    FrancisB, GreenM, PayneCD, eds. GLIM 4, the statistical system for generalized linear interactive modelling. Oxford: Oxford University Press, 1993.
  • 12
    Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Stat Med 1987; 6: 44967.
  • 13
    Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med 1987; 6: 46981.
  • 14
    Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 1979; 3: 46788.
  • 15
    Fechner RE. Histologic variants of infiltrating lobular carcinoma of the breast. Hum Pathol 1975; 6: 3738.
  • 16
    Manson JE, Martin KA. Postmenopausal hormone replacement therapy. N Engl J Med 2001; 345: 3440.
  • 17
    Mitka M. New advice for women patients about hormone therapy and the heart. JAMA 2001; 286: 907.
  • 18
    Schaad MA, Bonjour JP, Rizzoli R. Evaluation of hormone replacement therapy use by the sales figures. Maturitas 2000; 34: 18591.
  • 19
    Bakken K, Eggen AE, Lund E. Hormone replacement therapy in Norwegian women, 1996–1997. Maturitas 2001; 40: 13141.
  • 20
    Donker GA, Spreeuwenberg P, Bartelds AIM, van der Velden K, Foets M. Hormone replacement therapy: changes in frequency and type of prescription by Dutch GP's during the last decade of the millennium. Fam Pract 2000; 14: 50813.
  • 21
    Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 1997; 145: 53645.
  • 22
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 104759.
  • 23
    Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287: 73441.
  • 24
    Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000; 88: 25707.
  • 25
    Fitzgerald O'Connor I, Shembekar MV, Shousha S. Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J Clin Pathol 1998; 51: 9358.
  • 26
    Frost AR, Terahata S, Yeh IT, Siegel RS, Overmoyer B, Silverberg SG. An analysis of prognostic features in infiltrating lobular carcinoma of the breast. Mod Pathol 1995; 8: 8306.